Purpose. Chlamydiatrachomatis is responsible for trachoma-associated blindness as well as the most common sexually transmitted bacterial infection worldwide, although the genovars for the former are typically A-C, whilst for the latter they are D-K and for the uncommon infection lymphogranuloma venereum they are L1-3. Nucleotide variations within the ompA gene facilitate the identification of C. trachomatis genovars. This study describes a colorimetric multiplex PCR/RLB typing assay (mPCR-RLB) directed to the VD2 region of the ompA gene for general C. trachomatis positivity and the identification of 14 individual C. trachomatis genovars.
INTRODUCTION
Chlamydia trachomatis is the predominant sexually transmitted bacterial infection diagnosed worldwide, with an estimated 100 million new infections each year [1] . Urogenital infections are the most common and are often associated with urethritis or, if complicated, epididymitis in men, and cervicitis, pelvic inflammatory disease, ectopic pregnancy or tubal infertility in women [2, 3] . In pregnant women, the infection has been associated with adverse pregnancy outcomes such as preterm labour and may be transmitted vertically to the newborn during vaginal birth, potentially resulting in neonatal conjunctivitis or pneumonitis [4] [5] [6] .
C. trachomatis infections are also responsible for trachomaassociated blindness and lymphogranuloma venereum (LGV), causing invasive infections and subsequent severe inflammatory responses [7] [8] [9] . The World Health Organization reported that near to 1.3 million people are blind due to trachoma. Although the disease has been eliminated from many developed countries, people from developing countries in regions such as Africa, the Middle East, South America, Asia and the Pacific still suffer from this disease, accounting for nearly 15 per cent of global blindness [10] . Australia remains the only developed country to have endemic levels of trachoma within Aboriginal communities in the Northern Territory, South Australia and Western Australia [11] .
C. trachomatis strains are divided into 15 distinct genovars according to the sequence variation within the ompA gene [12] . On the basis of pathogenic potential, genovars A, B, Ba and C are commonly associated with trachoma, while D to K are associated with urogenital infections and L1, L2 and L3 cause LGV. C. trachomatis genovars can be subdivided into three distinct phylogenetic clades or groups based on the ompA gene: group B (B, Ba, D, Da, E, L1, L2 and L2a), group C (A, C, H, I, Ia, J, K and L3) and an intermediate group (F and G) [13] .
The current guidelines for laboratory diagnosis of C. trachomatis infections recommend nucleic acid amplification tests (NAATs), [4, 14] . Thus commercial DNA or RNA amplification tests are commonly used in the clinical setting to detect C. trachomatis, with more recently developed dual detection systems for C. trachomatis and Neisseria gonorrhoeae being implemented [15] [16] [17] .
The long-established typing methods for C. trachomatis were based on serotyping of the major outer membrane protein (MOMP) and, later on, genotyping of the ompA gene [12, [18] [19] [20] [21] [22] . New techniques with higher discriminating capacity have been developed in recent years, such as multilocus sequence typing (MLST), multilocus variable number tandem repeat analysis (MLVA) and whole-genome sequencing (WGS) [23] [24] [25] [26] [27] . Although these new techniques are accurate methods for C. trachomatis genotyping and optimal for epidemiological and evolutionary studies and studying the dynamics of transmission, they are laborious and expensive and are not useful for the detection of multiple C. trachomatis infections or the rapid screening required for diagnostic use in clinical settings. A technology that can be integrated into a clinical diagnostic laboratory is important for the rapid detection of C. trachomatis infections and will be decisive for guiding therapy choice.
Previously we published a paper on the development of a highly sensitive and specific nested VD2 PCR-reverse line blot that used chemiluminescence detection in the identification of nine urogenital genovars [28] . Here we describe and validate a more rapid and easier colorimetric multiplex PCR-reverse line blot assay (mPCR-RLB) for the identification of 14 different genovars of C. trachomatis, including the identification of genovars commonly associated with urogenital infections, trachoma and LGV.
METHODS
Reference C. trachomatis strains and other pathogenic micro-organisms DNA-purified extracts of cell culture isolates representative of 14 prototypic C. trachomatis genovars originally obtained from the ATCC Global Bioresource Center (Manassas, VA, USA) were used to assess the analytical sensitivity and specificity of the C. trachomatis-specific primers and probes. The isolates included the following: A-Har-13 (VR-571B), B-HAR-36 (VR-573), C-TW-3 (VR-1477), D-UW-3/Cx (VR-885), E-Bour (VR-348B), FIC-Cal-3 (VR-346), G-UW-57/ Cx (VR-878), H-UW-43/Cx (VR-879), I-UW-12/Ur (VR-880), J-UW-36/Cx (VR-886), K-UW-31/Cx (VR-887), L1-440 (VR-901B), L2-434 (VR-902B) and L3-404 (VR-903). Other pathogenic micro-organisms and cell lines (Mycoplasm genitalium, N. gonorrhoeae, Trichomonas vaginalis, adenovirus, HSV1, HSV2, Ureaplasma urealyticum, Ureaplasma sp., A 549 cell line) were also included for analytical specificity. The C. trachomatis copy number was determined for each DNA extract by quantitative PCR (qPCR) in conjunction with a quantified C. trachomatis standard (Advanced Biotechnologies, Inc., Columbia, MD, USA) as reported by Stevens et al. [20] .
Clinical samples
Purified DNA from a total of 90 clinical C. trachomatispositive anogenital specimens were consecutively selected from two studies recruiting participants from sexual health services in Melbourne, Australia [29, 30] . Twenty-nine of these (15 from men who have sex with men, 8 from women and 6 from heterosexual men) were pre-treatment baseline remainders of rectal and vaginal swabs or urine samples previously found to be C. trachomatis-positive using qPCR as part of the retest after Chlamydia trachomatis (REACT) trial [29] . The other 71 samples were rectal swabs from the REARS study investigating C. trachomatis in asymptomatic men who have sex with men, and had previously been found to be C. trachomatis-positive using qPCR and multilocus sequence typing (MLST) [30] 
Design of amplification primers and capture probes
The set of amplification primers comprising three forward and three reverse consensus primers has been described previously [31] . Briefly, the amplification primer set was designed to amplify a fragment of 157 to 160 bp from the omp1 VD2 region of different C. trachomatis genovars, and the reverse primers were biotin-labelled at the 5¢ end to allow colorimetric detection. The sequences are shown in Table 1 .
Oligonucleotide capture probes (IDT, Australia) that were directed against the VD2 region of the MOMP gene and specific for 14 different urogenital genovars of C. trachomatis were designed or modified from our previous publication [28] using the primer/probe selection software Oligo (www. oligo.net). The oligonucleotide probes were synthesized with a 5¢-terminal amino group. Three additional probes were designed to identify the three principal groups of C. trachomatis genovars: group B (B/Ba, D, E, L1 and L2; previously described [25] ) group C (A, C, H, I, J, K and L3) and the intermediate group (F and G) ( Table 1) . A cocktail of these probes was used for overall detection of C. trachomatis.
The amplification primers and capture probes were designed to allow simultaneous amplification and hybridization in a multiplex reaction without loss of sensitivity, as follows: similar melting temperature (Tm); length, 18 to 30 bp; moderate, weak, or no secondary structure; and no dimer formation. The optimal concentration of the oligoprobes used and the melting temperatures are shown in Table 1 .
Multiplex PCR amplification and probe hybridization Multiplex PCR was performed using the set of amplification primers that was described previously with minor modifications [31] . Briefly, the multiplex PCR was standardized in a final volume of 25 µl containing: 5 µl of isolated DNA, 1ÂGeneAmp PCR Buffer II, 0.2 mM dNTPs, 2.5 mM MgCl2, 12.5 pmol of primers (momp Fw1, Fw2, Fw3 and momp rv1 bio, rv2bio, rv3 bio), 1 U AmpliTaq Gold DNA polymerase (Applied Biosystems, Foster City, CA, USA) and molecular-grade nuclease-free sterile water. The PCR cycling conditions were: a 9 min preheating step at 94 C, followed by 40 cycles of amplification (30 s at 94 C, 45 s at 60 C and 45 s at 72 C) and a final 5 min elongation step at 72 C. Each amplification experiment included positive standards (serial dilutions of DNA from C. trachomatis genovar D/VR-885 from 1Â10 3 to 1 copy per reaction, and a negative control (water). The PCR products were visualized on a 2 % agarose gel stained with Gelgreen (Biotium, Hayward, CA, USA).
RLB and colorimetric detection
The binding of oligonucleotide probes, reverse hybridization and colorimetric detection were performed based on previously described protocols with several modifications [28, 32] . Briefly, the oligonucleotide probes were synthesized with a 5¢-terminal amino group, which was used to covalently link the oligonucleotides to an activated negatively charged nylon membrane (Biodyne C, Pall Corporation) [28] . During the standardization process, the probes were fixed at different concentrations to determine the optimal concentrations. For amplicon hybridization, 10 µl of each PCR product was added to 150 µl of 2Â sodium chloride, sodium phosphate and EDTA (SSPE)/0.1 % sodium dodecyl sulphate (SDS) and denatured for 10 min at 99 C before being cooled in ice. The membrane, previously linked with the oligonucleotide probes, was incubated for 5 min at room temperature in 2ÂSSPE/0.1 % SDS and placed in a miniblotter in such a way that the slots were perpendicular to the line pattern of the applied oligonucleotides. Each slot was filled with diluted PCR product from a single sample and hybridized for 45 min at 56 C. The samples were removed and the membrane was washed twice in 2ÂSSPE/0.5 % SDS for 10 min at 58 C, incubated with diluted peroxidaselabelled streptavidin conjugate in 1ÂSSPE/0.1 % SDS for 30 min and washed twice in 1ÂSSPE/0.1 % SDS. For colorimetric detection, the membrane was incubated for 5 min in 1Âcitrate buffer, followed by incubation for 5 min at room temperature with a substrate solution containing citrate solution, 0.01 % hydrogen peroxide, 0.1 % 3,3¢,5,5¢-tetramethylbenzidine (TMB) and 40 % dimethylformamide (DMF). The reaction was stopped by washing the membrane with deionized water for 2 min. The membrane was placed on a clean surface to dry at room temperature.
Evaluation of mPCR-RLB analytical performance
To determine the limits of detection of the assay, standard curves for the mPCR-RLB were completed using quantified DNA of the 14 different reference genovars at concentrations of 1Â10 5 copies per reaction serially diluted to 1 copy. Each standard curve was tested in triplicate. The limits of detection of the mPCR obtained by gel and by colorimetric RLB were compared with those obtained using a quantitative PCR (qPCR) that had been developed previously by our group [20] (Table 2) .
To test for potential cross-reactivity with other organisms, samples that were positive for M. genitalium, N. gonorrhoeae, T. vaginalis, adenovirus, HSV1, HSV2, U. urealyticum and Ureaplasma sp. were tested in addition to DNA extracted from the A549 cell line.
Purified DNA of 40 blind samples of C. trachomatis reference strains and other pathogenic micro-organisms and cell lines previously genotyped by qPCR were tested by an operator blinded to the identity of each sample.
To determine sensitivity in clinically confirmed C. trachomatis-positive samples, 90 clinical samples from the REACT and REARS studies were tested by an operator blinded to the original genovar result.
PCR purification and sequencing PCR product purification was performed using the Agencourt AMPure XP PCR purification kit (Agencourt Bioscience Corp., Beverly, MA, USA) following the manufacturer's instructions. DNA concentrations were estimated using a Qubit fluorometer (Invitrogen). Sanger sequencing of the purified PCR products was performed at the Australian Genome Research Facility (Brisbane, Queensland, Australia). The sequencing data were analysed using Geospiza's Finch TV version 1.4 software (PerkinElmer, Seattle, USA) and Sequencher 4.8 software (Gene Codes Corporation, Michigan, USA). Individual sequences for each sample were compared with the sequences available in the GenBank database using the National Center for Biotechnology Information BLAST program (http://www.ncbi. nlm.nih.gov/BLAST/).
RESULTS

Evaluation of mPCR-RLB's analytical performance
Amplification using the multiplex PCR primer mix resulted in bands of 157/160 bp. Serial dilutions of each of the 14 reference genovars produced visually detectable amplification products at all dilutions down to 10 copies per reaction (Fig. 1) . Using the RLB assay, the limit of detection improved by 10-fold, with visually detectable products down to 1 copy per reaction for all the genovars (Table 2) . A comparison of the sensitivity of the mPCR-RLB with a qPCR previously developed by our group showed that the mPCR-RLB was more sensitive in the detection of the 14 different reference strains, 1 copy versus 10-40 copies of the qPCR ( Table 2 ).
The 14 different oligoprobes hybridized with the nucleotide sequence of the corresponding C. trachomatis genovar and no cross-reaction was detected between the genovars. In addition, each C. trachomatis genovar matched specifically to the group probe (B, C or intermediate) and to the consensus probe for C. trachomatis positivity (Fig. 2 ). An example of the detection of genovars associated with trachoma, urogenital infections and LGV is shown in Fig. 2 . A representative example of the reproducibility of the RLB assay in the detection of individual C. trachomatis genovars is shown in Fig. 3 .
A group of 40 blinded samples that included reference strains of single C. trachomatis genovars and other pathogenic micro-organisms, previously analysed using qPCR, were tested. A total of 24 (60 %) samples were identified as being positive for C. trachomatis infection and 16 (40 %) were negative (Table 3) . Fourteen different genovars were identified from the C. trachomatis-positive samples. None of the samples showed infections by multiple variants. Comparison of the mPCR-RLB with the original qPCR result showed 100 % agreement (kappa value=1) for the detection of the C. trachomatis reference strains. No cross-reaction was observed with other pathogenic micro-organisms or cell lines.
Analysis of clinical samples previously analysed by qPCR
A total of 90 clinical samples from the REARS and REACT studies that had previously been found to be C. trachomatispositive by qPCR were analysed using the mPCR-RLB assay. A total of 88 samples (97.8 %) were found to be C. trachomatis-positive by the mPCR-RLB using the general C. trachomatis detection and the group identification probes. The analysis of specific genovar identification showed that 84 samples (93.4 %) were C. trachomatis genovar-positive. Seven different genovars were identified (Table 4a ). Single C. trachomatis infections were detected in 81 of these samples (96.4 %) and multiple infections were detected in 3 samples (3.6 %).
When the mPCR-RLB and qPCR results were compared at the group and genovar identification level, the assays showed 96.6% and 92.2 % concordance, respectively (Table 4b ). Four of the seven samples with discrepant results at the genovar level were identified as genovar B using qPCR and were strongly positive for group B as well as C. trachomatis general detection by the mPCR-RLB assay, but were not positive for a specific genovar. Two of the seven samples were weakly positive for genovar J using the qPCR but were negative on the mPCR-RLB assay, and one sample showed a multiple infection for genovars G and J using the mPCR-RLB but was only positive for genovar G using the qPCR (Table 4c ). After DNA purification of the seven amplified products, only four samples could be sequenced and all of them were identified as genovar Ba (strain Ba-CDC1).
DISCUSSION
In this study, we have developed an in-house colorimetric mPCR-RLB assay for the easy, rapid and high-throughput identification of 14 different genovars of C. trachomatis associated with urogenital infections, trachoma and LGV. The combination of a sensitive multiplex PCR for the amplification of the VD2 region of the omp1 gene followed by the rapid colorimetric detection of hybridized biotinlabelled amplicons to C. trachomatis genovar-specific and group-specific probes allowed us to detect as few as 1-10 copies of the different reference strains analysed. The limits of detection were comparable to or better than those of previous reports using the omp1 gene as the target [28, 31, [33] [34] [35] . When comparing the sensitivity of the mPCR-RLB with a qPCR previously developed by our group [20] , the mPCR-RLB was slightly more sensitive in the detection of the 14 different reference strains (1-10 vs 10-40 copies, respectively). This higher level of detection may be due in part to the smaller amplified products generated in the mPCR compared to the amplified products of the qPCR (157 to 160 bp vs 266 to 278 bp) and to the colorimetric method used in the RLB assay increasing signal detection by 10-fold for all the genovars included in the assay.
The increasing prevalence of C. trachomatis infections worldwide and the potentially serious sequelae that occur if they are left undiagnosed or untreated encouraged us to develop the in house mPCR-RLB to be used in both research and diagnostic settings. After analysing blinded reference strains of C. trachomatis and other pathogenic micro-organisms, the mPCR-RLB assay was shown to be a highly accurate and efficient method to detect the most common C. trachomatis genovars associated with urogenital infections (genovars D, E, F, G, H, I, J and K), trachoma (genovars A, B/Ba and C) and LGV (genovars L1, L2 and L3). The method also allows the overall detection of C. trachomatis and the identification of genovar groups in the same assay, providing broader functionality for this test. These additional probes can also be used as internal controls, making the assay highly reliable. The analysis of clinical samples by using our mPCR-RLB confirmed the high sensitivity of the mPCR-RLB, with C. trachomatis infections being detected in 97.8 % of the cases.
When comparing the mPCR-RLB to the qPCR approach, we demonstrated excellent agreement with respect to genovar identification, with only seven (7.8 %) discrepant specimens. The mPCR-RLB assay was designed to identify genovar B/Ba (strain Apache 2) but no other strains of genovar Ba. Four of the discrepant samples were genovar Ba (strain Ba-CDC1), as confirmed by sequencing. These results clearly show the high specificity of the RLB, which allowed the identification of the four samples as C. trachomatis-positive and belonging to group B, but missed specific identification of genovar Ba (strain-CDC1). There is only a two-nucleotide difference between the sequences of genovar B and genovar Ba (strain-CDC1) in the region where the probe B/Ba was designed. This is an advantage of the mPCR-RLB, because the assay will not show cross-reactions even for closely related variants and will inform users when a mutation or change that has to be elucidated is present. The other two samples that were positive by qPCR and negative by the mPCR-RLB had been identified as genovar J. These samples were previously very weakly positive according to the qPCR (Cq values of 50 and 42, respectively) and multiple freeze/thaw cycles could potentially result in the loss or degradation of C. trachomatis DNA. These two samples could not be retested on the qPCR or sequenced due to insufficient quantities of DNA. The last sample with partially discrepant results was positive for genovars G and J on the mPCR-RLB, but only positive for genovar G by qPCR. One of the principal advantages of using RLB assays is the ability to identify mixed infections, even in samples with low infection loads. Multiple infections with two or more genotypes of C. trachomatis are not a rare event and seem to be correlated with events of genetic recombination between strains of different genotypes, as previously reported [36, 37] . Although our size sample was low, we detected multiple infections in 3.6 % of the samples analysed in our study using our RLB, compared to 2.2 % when using qPCR. Similarly, in another study, where 494 men with similar characteristics to the participants of our study were tested using qPCR, 2.4 % of the samples had multiple infections [20] . The similar prevalence of multiples C. trachomatis infections found in both studies and the use of different techniques could suggest that the presence of multiple infections in this population is low.
Studies analysing the ompA gene using hybridization techniques have been widely employed [28, 33, [38] [39] [40] . All of these studies have used primary and nested PCRs to improve the sensitivity in the detection of the genovars. Although a nested PCR is a good method for the detection of C. trachomatis genovars, it increases the possibility of contamination significantly. Two of these studies used chemiluminescent detection, which requires special equipment [28, 33] , and the other three used overnight hybridization when using colorimetric detection, which extended the time of the experiments considerably [38] [39] [40] . The in-house mPCR-RLB developed by us overcomes all of these problems and is the only currently developed technique that allows the generic and specific detection of C. trachomatis infections in the same assay, which is optimal for screening use.
Although the number of samples was low, we observed that a higher number of infections by genovar E and F were found in heterosexual men and women, while in men that have sex with men genovars G and D were the most common, as reported previously by our group and by others [30, 35, 37] .
The samples that were infected by genovars L2 and Ba (strain CDC1) belonged to men that have sex with men participating in the REARS study [30, 41] . Genovar L2 has commonly been associated with lymphogranuloma venereum and in recent years some outbreaks of LGV due to C. trachomatis LGV genovar L2b have been reported in Europe, North America and Australia, mainly among HIVpositive men who have sex with men [42] .
Although genovars B and Ba are commonly found in ocular sites and are associated with trachoma, they also seem to be transmitted sexually, as described in different studies [43] [44] [45] and reported for men who have sex with men [30, 46] . However, the majority of these studies did not give information about the specific strain involved. The genovar Ba (strain CDC1) has also been found in urogenital samples from the United States [47] [48] [49] . More genotyping studies have to be performed worldwide, indicating which specific genovar B strains are infecting the different anatomical sites to clarify if those genovar B or Ba strains associated with trachoma are the same or different from those transmitted sexually.
The ability to perform a diagnostic test to identify and differentiate LGV strains from non-LGV strains in high-risk populations is essential to establish the appropriate treatment course. Likewise, it is important to identify possible treatment failures and monitor infection control. Some researchers have shown that a considerable proportion of cases of LGV may be asymptomatic at clinical presentation and they will be missed unless routine genotyping of rectal chlamydia to the genovar level is performed [30, 42, 47] . Furthermore, it has been established that different doses of antibiotics and different treatment times are required for the management of LGV infection compared with the treatment and doses required to manage other C. trachomatis infections [22] .
Our mPCR/RLB assay has multiple advantages. One of these is the fact that only one PCR is performed for the amplification of the different genovars, which reduces the likelihood of contamination and saves time. The size of the amplified product is small, which allows the analysis of a variety of specimen types that may have low C. trachomatis copy numbers, including urine samples, cervical and anal smears, or self-collected swabs. This assay is also an excellent method for the detection of single and multiple C. trachomatis infections, permitting the identification of general infection and specific genovar group typing for a rapid screening analysis. The facility to perform it without specialized equipment and the short time required for testing are all positive aspects for its implementation in diverse clinical settings.
In conclusion, the mPCR-RLB developed is an easy, rapid, sensitive and accurate method for the identification of the most common genovars associated with urogenital infections, trachoma and LGV that can be easily implemented in diagnostic settings, allowing targeted clinical treatment regimes.
Funding information
Support was received through an Australian National Health and Medical Research Council Program grant (APP 568971). 
